De Novo Chronic Graft-Versus-Host Disease in Marrow Graft Recipients Given Methotrexate and Cyclosporine: Risk Factors and Survival

Biology of Blood and Marrow Transplantation

Volumn 6, Issue 6, 2000, Pages 633-639

  Wagner, John L ^a,b   Seidel, Kristy ^a   Boeckh, Michael ^a   Storb, Rainer ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

De novo chronic graft versus host disease; Risk factors; Survival

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE;

ADOLESCENT; ADULT; ALLOTRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; FEMALE; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY TEST; HUMAN; IMMUNOLOGY; INFANT; MALE; MORTALITY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; FEMALE; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; METHOTREXATE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033648054     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(00)70029-2     Document Type: Article

References (24)

1. Sullivan KM. Acute and chronic graft-versus-host disease in man. Int J Cell Cloning. 1986;4:42-93.
2. Wingard JR, Piantadosi S, Vogelsang GB, et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood. 1989;74:1428-1435.
3. Storb R, Prentice RL, Sullivan KM, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med. 1983;98:461-466.
4. Storb R, Leisenring W, Anasetti C, et al. Methotrexate and cyclosporine for graft-versus-host disease prevention: what length of therapy with cyclosporine? Biol Blood Marrow Transplant. 1997;3:194-201.
5. Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990;75:2459-2464.
6. Ochs LA, Miller WJ, Filipovich AH, et al. Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation. Bone Marrow Transplant. 1994;13:455-460.
7. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729-735.
8. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204-217.
9. Shulman HM, Sale GE, Lerner KG, et al. Chronic cutaneous graft-versus-host disease in man. Am J Pathol. 1978;91:545-570.
10. Sale GE, Shulman HM, Schubert MM, et al. Oral and ophthalmic pathology of graft versus host disease in man: predictive value of the lip biopsy. Hum Pathol. 1981;12:1022-1030.
11. Epstein O, Thomas HC, Sherlock S. Primary biliary cirrhosis is a dry gland syndrome with features of chronic graft-versus-host disease. Lancet. 1980;1:1166-1168.
12. Jack MK, Jack GM, Sale GE, Shulman HM, Sullivan KM: Ocular manifestations of graft-v-host disease. Arch Ophthalmol. 1983; 101:1080-1084.
13. McDonald GB, Sullivan KM, Schuffler MD, Shulman HM, Thomas ED. Esophageal abnormalities in chronic graft-versus-host disease in humans. Gastroenterology. 1981;80:914-921.
14. Clark JG, Crawford SW, Madtes DK, Sullivan KM. Obstructive lung disease after allogeneic marrow transplantation. Ann Intern Med. 1989;111:368-376.
15. Burke CM, Theodore J, Dawkins KD, et al. Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation. Chest. 1984;86:824-829.
16. Schubert MA, Sullivan KM, Schubert MM, et al. Gynecological abnormalities following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1990;5:425-430.
17. Reyes MG, Noronha P, Thomas W Jr, Heredia R: Myositis of chronic graft versus host disease. Neurology. 1983;33:1222-1224.
18. Storb R, Doney KC, Thomas ED, et al. Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients. Blood. 1982;59:236-246.
19. Niederwieser D, Pepe M, Storb R, Witherspoon R, Longton G, Sullivan K: Factors predicting chronic graft-versus-host disease and survival after marrow transplantation for aplastic anemia. Bone Marrow Transplant. 1989;4:151-156.
20. Storb R, Deeg HJ, Fisher LD, et al. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood. 1988;71:293-298.
21. Boström L, Ringdén O, Jacobsen N, Zwaan F, Nilsson B. A European multicenter study of chronic graft-versus-host disease: the role of cytomegalovirus serology in recipients and donors: acute graft-versus-host disease, and splenectomy. Transplantation. 1990;49:1100-1105.
22. Lonnqvist B, Ringden O, Wahren B, Gahrton G, Lundgren G. Cytomegalovirus infection associated with and preceding chronic graft-versus-host disease. Transplantation. 1984;38:465-468.
23. Gale RP, Bortin MM, van Bekkum DW, et al. Risk factors for acute graft-versus-host disease. Br J Haematol. 1987;67:397-406.
24. Carlens S, Ringden O, Remberger M, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant. 1998;22:755-761.